Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors

US12247033B2 · kind B2 · utility

Assignee

• GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

• Adam Kenneth Charnley · Collegeville, US
• Janos Botyanszki · Camarillo, US
• Xiaoyang Dong · Collegeville, US
• Philip G. Humphreys · Stevenage, GB
• Bryan Wayne King · Blue Bell, US
• Kimberly Katherine Marcus · Collegeville, US
• Joseph E. Pero · Harleysville, US
• Alexander Joseph Reif · Holland, US
• Daohua Zhang · Collegeville, US
• Attiq Rahman · Collegeville, US
• Kenneth A. Newlander · West Chester, US
• Kenneth Wiggall · Collegeville, US
• Joshi M. Ramanjulu · Collegeville, US

Key dates

• Filing date: Feb 26, 2024
• Grant date: Mar 11, 2025
• Expiry date: Feb 26, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of Formula (I), compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.